Can we unlock the potential of IGF-1R inhibition in cancer therapy?

Helen King, Tamara Aleksic, Paul Haluska, Valentine M. Macaulay

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

IGF-1R inhibitors arrived in the clinic accompanied by optimism based on preclinical activity of IGF-1R targeting, and recognition that low IGF bioactivity protects from cancer. This was tempered by concerns about toxicity to normal tissue IGF-1R and cross-reactivity with insulin receptor (InsR). In fact, toxicity is not a show-stopper; the key issue is efficacy. While IGF-1R inhibition induces responses as monotherapy in sarcomas and with chemotherapy or targeted agents in common cancers, negative Phase 2/3 trials in unselected patients prompted the cessation of several Pharma programs. Here, we review completed and on-going trials of IGF-1R antibodies, kinase inhibitors and ligand antibodies. We assess candidate biomarkers for patient selection, highlighting the potential predictive value of circulating IGFs/IGFBPs, the need for standardized assays for IGF-1R, and preclinical evidence that variant InsRs mediate resistance to IGF-1R antibodies. We review hypothesis-led and unbiased approaches to evaluate IGF-1R inhibitors with other agents, and stress the need to consider sequencing with chemotherapy. The last few years were a tough time for IGF-1R therapeutics, but also brought progress in understanding IGF biology. Even failed studies include patients who derived benefit; they should be investigated to identify features distinguishing the tumors and host environment of responders from non-responders. We emphasize the importance of incorporating biospecimen collection into trial design, and wording patient consents to allow post hoc analysis of trial material as new data become available. Such information represents the key to unlocking the potential of this approach, to inform the next generation of trials of IGF signalling inhibitors.

Original languageEnglish (US)
Pages (from-to)1096-1105
Number of pages10
JournalCancer Treatment Reviews
Volume40
Issue number9
DOIs
StatePublished - Oct 1 2014

Fingerprint

Antibodies
Drug Therapy
Neoplasms
Insulin-Like Growth Factor Binding Proteins
Insulin Receptor
Sarcoma
Patient Selection
Phosphotransferases
Therapeutics
Biomarkers
Ligands
Inhibition (Psychology)
Recognition (Psychology)
Optimism

Keywords

  • IGF
  • IGF-1R cancer therapy
  • Predictive biomarker
  • Therapeutic antibody
  • Type 1 IGF receptor
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Can we unlock the potential of IGF-1R inhibition in cancer therapy? / King, Helen; Aleksic, Tamara; Haluska, Paul; Macaulay, Valentine M.

In: Cancer Treatment Reviews, Vol. 40, No. 9, 01.10.2014, p. 1096-1105.

Research output: Contribution to journalArticle

King, H, Aleksic, T, Haluska, P & Macaulay, VM 2014, 'Can we unlock the potential of IGF-1R inhibition in cancer therapy?', Cancer Treatment Reviews, vol. 40, no. 9, pp. 1096-1105. https://doi.org/10.1016/j.ctrv.2014.07.004
King, Helen ; Aleksic, Tamara ; Haluska, Paul ; Macaulay, Valentine M. / Can we unlock the potential of IGF-1R inhibition in cancer therapy?. In: Cancer Treatment Reviews. 2014 ; Vol. 40, No. 9. pp. 1096-1105.
@article{52800e8e49254d619e9b5341de6bb8bd,
title = "Can we unlock the potential of IGF-1R inhibition in cancer therapy?",
abstract = "IGF-1R inhibitors arrived in the clinic accompanied by optimism based on preclinical activity of IGF-1R targeting, and recognition that low IGF bioactivity protects from cancer. This was tempered by concerns about toxicity to normal tissue IGF-1R and cross-reactivity with insulin receptor (InsR). In fact, toxicity is not a show-stopper; the key issue is efficacy. While IGF-1R inhibition induces responses as monotherapy in sarcomas and with chemotherapy or targeted agents in common cancers, negative Phase 2/3 trials in unselected patients prompted the cessation of several Pharma programs. Here, we review completed and on-going trials of IGF-1R antibodies, kinase inhibitors and ligand antibodies. We assess candidate biomarkers for patient selection, highlighting the potential predictive value of circulating IGFs/IGFBPs, the need for standardized assays for IGF-1R, and preclinical evidence that variant InsRs mediate resistance to IGF-1R antibodies. We review hypothesis-led and unbiased approaches to evaluate IGF-1R inhibitors with other agents, and stress the need to consider sequencing with chemotherapy. The last few years were a tough time for IGF-1R therapeutics, but also brought progress in understanding IGF biology. Even failed studies include patients who derived benefit; they should be investigated to identify features distinguishing the tumors and host environment of responders from non-responders. We emphasize the importance of incorporating biospecimen collection into trial design, and wording patient consents to allow post hoc analysis of trial material as new data become available. Such information represents the key to unlocking the potential of this approach, to inform the next generation of trials of IGF signalling inhibitors.",
keywords = "IGF, IGF-1R cancer therapy, Predictive biomarker, Therapeutic antibody, Type 1 IGF receptor, Tyrosine kinase inhibitor",
author = "Helen King and Tamara Aleksic and Paul Haluska and Macaulay, {Valentine M.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.ctrv.2014.07.004",
language = "English (US)",
volume = "40",
pages = "1096--1105",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Can we unlock the potential of IGF-1R inhibition in cancer therapy?

AU - King, Helen

AU - Aleksic, Tamara

AU - Haluska, Paul

AU - Macaulay, Valentine M.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - IGF-1R inhibitors arrived in the clinic accompanied by optimism based on preclinical activity of IGF-1R targeting, and recognition that low IGF bioactivity protects from cancer. This was tempered by concerns about toxicity to normal tissue IGF-1R and cross-reactivity with insulin receptor (InsR). In fact, toxicity is not a show-stopper; the key issue is efficacy. While IGF-1R inhibition induces responses as monotherapy in sarcomas and with chemotherapy or targeted agents in common cancers, negative Phase 2/3 trials in unselected patients prompted the cessation of several Pharma programs. Here, we review completed and on-going trials of IGF-1R antibodies, kinase inhibitors and ligand antibodies. We assess candidate biomarkers for patient selection, highlighting the potential predictive value of circulating IGFs/IGFBPs, the need for standardized assays for IGF-1R, and preclinical evidence that variant InsRs mediate resistance to IGF-1R antibodies. We review hypothesis-led and unbiased approaches to evaluate IGF-1R inhibitors with other agents, and stress the need to consider sequencing with chemotherapy. The last few years were a tough time for IGF-1R therapeutics, but also brought progress in understanding IGF biology. Even failed studies include patients who derived benefit; they should be investigated to identify features distinguishing the tumors and host environment of responders from non-responders. We emphasize the importance of incorporating biospecimen collection into trial design, and wording patient consents to allow post hoc analysis of trial material as new data become available. Such information represents the key to unlocking the potential of this approach, to inform the next generation of trials of IGF signalling inhibitors.

AB - IGF-1R inhibitors arrived in the clinic accompanied by optimism based on preclinical activity of IGF-1R targeting, and recognition that low IGF bioactivity protects from cancer. This was tempered by concerns about toxicity to normal tissue IGF-1R and cross-reactivity with insulin receptor (InsR). In fact, toxicity is not a show-stopper; the key issue is efficacy. While IGF-1R inhibition induces responses as monotherapy in sarcomas and with chemotherapy or targeted agents in common cancers, negative Phase 2/3 trials in unselected patients prompted the cessation of several Pharma programs. Here, we review completed and on-going trials of IGF-1R antibodies, kinase inhibitors and ligand antibodies. We assess candidate biomarkers for patient selection, highlighting the potential predictive value of circulating IGFs/IGFBPs, the need for standardized assays for IGF-1R, and preclinical evidence that variant InsRs mediate resistance to IGF-1R antibodies. We review hypothesis-led and unbiased approaches to evaluate IGF-1R inhibitors with other agents, and stress the need to consider sequencing with chemotherapy. The last few years were a tough time for IGF-1R therapeutics, but also brought progress in understanding IGF biology. Even failed studies include patients who derived benefit; they should be investigated to identify features distinguishing the tumors and host environment of responders from non-responders. We emphasize the importance of incorporating biospecimen collection into trial design, and wording patient consents to allow post hoc analysis of trial material as new data become available. Such information represents the key to unlocking the potential of this approach, to inform the next generation of trials of IGF signalling inhibitors.

KW - IGF

KW - IGF-1R cancer therapy

KW - Predictive biomarker

KW - Therapeutic antibody

KW - Type 1 IGF receptor

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84928758281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928758281&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2014.07.004

DO - 10.1016/j.ctrv.2014.07.004

M3 - Article

VL - 40

SP - 1096

EP - 1105

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 9

ER -